These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30683837)

  • 61. Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.
    Thol F; Yun H; Sonntag AK; Damm F; Weissinger EM; Krauter J; Wagner K; Morgan M; Wichmann M; Göhring G; Bug G; Ottmann O; Hofmann WK; Schambach A; Schlegelberger B; Haferlach T; Bowen D; Mills K; Ganser A; Heuser M
    Ann Hematol; 2012 Aug; 91(8):1221-33. PubMed ID: 22488406
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.
    Tefferi A; Guglielmelli P; Lasho TL; Coltro G; Finke CM; Loscocco GG; Sordi B; Szuber N; Rotunno G; Pacilli A; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Vannucchi AM
    Br J Haematol; 2020 Apr; 189(2):291-302. PubMed ID: 31945802
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of
    Segura-Díaz A; Stuckey R; Florido Y; González-Martín JM; López-Rodríguez JF; Sánchez-Sosa S; González-Pérez E; Sáez Perdomo MN; Perera MDM; de la Iglesia S; Molero-Labarta T; Gómez-Casares MT; Bilbao-Sieyro C
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290079
    [TBL] [Abstract][Full Text] [Related]  

  • 65. RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features.
    Coltro G; Rotunno G; Mannelli L; Mannarelli C; Fiaccabrino S; Romagnoli S; Bartalucci N; Ravenda E; Gelli E; Sant'Antonio E; Patnaik MM; Tefferi A; Vannucchi AM; Guglielmelli P
    Blood Adv; 2020 Aug; 4(15):3677-3687. PubMed ID: 32777067
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Targeted molecular characterization shows differences between primary and secondary myelofibrosis.
    Courtier F; Garnier S; Carbuccia N; Guille A; Adélaide J; Chaffanet M; Hirsch P; Paz DL; Slama B; Vey N; Ugo V; Delhommeau F; Rey J; Birnbaum D; Murati A
    Genes Chromosomes Cancer; 2020 Jan; 59(1):30-39. PubMed ID: 31340059
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation.
    Gagelmann N; Ditschkowski M; Bogdanov R; Bredin S; Robin M; Cassinat B; Shahswar R; Thol F; Heuser M; Socié G; Beelen D; Triviai I; Badbaran A; Kröger N
    Blood; 2019 May; 133(20):2233-2242. PubMed ID: 30760453
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mutational profiling in myelofibrosis: implications for management.
    Bose P; Verstovsek S
    Int J Hematol; 2020 Feb; 111(2):192-199. PubMed ID: 31630335
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective.
    Savani M; Dulery R; Bazarbachi AH; Mohty R; Brissot E; Malard F; Bazarbachi A; Nagler A; Mohty M
    Br J Haematol; 2021 Nov; 195(4):495-506. PubMed ID: 33881169
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cellular taxonomy of the preleukemic bone marrow niche of acute myeloid leukemia.
    Goda C; Kulkarni R; Bustos Y; Li W; Rudich A; Balcioglu O; Chidester S; Urs AP; Karunasiri M; Al-Marrawi Y; Korn E; Kanna S; Garfinkle EAR; Shah N; Wooten A; Mundy-Bosse B; Sehgal L; Zhang B; Marcucci G; Mardis ER; Garzon R; Bowman RL; Viny AD; Miles LA; Miller KE; Dorrance AM
    Leukemia; 2024 Oct; ():. PubMed ID: 39358541
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Function of serine/arginine-rich splicing factors in hematopoiesis and hematopoietic malignancies.
    Zhang H; Zhu H; Peng H; Sheng Y
    Cancer Cell Int; 2024 Jul; 24(1):257. PubMed ID: 39034387
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Generation and Characterization of Induced Pluripotent Stem Cells Carrying An ASXL1 Mutation.
    Wang W; Zhang X; Li Y; Shen J; Li Y; Xing W; Bai J; Shi J; Zhou Y
    Stem Cell Rev Rep; 2024 Oct; 20(7):1889-1901. PubMed ID: 38884929
    [TBL] [Abstract][Full Text] [Related]  

  • 73. U2AF1 in various neoplastic diseases and relevant targeted therapies for malignant cancers with complex mutations (Review).
    Nian Q; Li Y; Li J; Zhao L; Rodrigues Lima F; Zeng J; Liu R; Ye Z
    Oncol Rep; 2024 Jan; 51(1):. PubMed ID: 37975232
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Incidence of blast phase in myelofibrosis according to anemia severity.
    Mora B; Maffioli M; Rumi E; Guglielmelli P; Caramella M; Kuykendall A; Palandri F; Iurlo A; De Stefano V; Kiladjian JJ; Elli EM; Polverelli N; Gotlib J; Albano F; Silver RT; Benevolo G; Ross DM; Devos T; Borsani O; Barbui T; Porta MGD; Bertù L; Komrokji R; Vannucchi AM; Passamonti F
    EJHaem; 2023 Aug; 4(3):679-689. PubMed ID: 37601878
    [TBL] [Abstract][Full Text] [Related]  

  • 75. High molecular risk variants, severe thrombocytopenia and large unstained cells count affect the outcome in primary myelofibrosis.
    Kanduła Z; Janowski M; Więckowska B; Paczkowska E; Mroczkowska-Bękarciak A; Sobas M; Lewandowski K
    J Appl Genet; 2023 Sep; 64(3):479-491. PubMed ID: 37507589
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
    Tefferi A; Alkhateeb H; Gangat N
    Blood Cancer J; 2023 Jul; 13(1):108. PubMed ID: 37460550
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments.
    Chifotides HT; Verstovsek S; Bose P
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444441
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Clinical and genetic characteristics of young patients with myeloproliferative neoplasms].
    Zhang MY; Bao M; Shi DY; Shi HX; Liu XL; Xu N; Duan MH; Zhuang JL; Du X; Qin L; Hui WH; Liang R; Wang MF; Chen Y; Li DY; Yang W; Tang GS; Zhang WH; Kuang X; Su W; Han YQ; Chen LM; Xu JH; Liu ZG; Huang J; Zhao CT; Tong HY; Hu JD; Chen CY; Chen XQ; Xiao ZJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):193-201. PubMed ID: 37356980
    [No Abstract]   [Full Text] [Related]  

  • 79. Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future.
    Duminuco A; Nardo A; Giuffrida G; Leotta S; Markovic U; Giallongo C; Tibullo D; Romano A; Di Raimondo F; Palumbo GA
    J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983189
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Acute Myeloid Leukemia Following Myeloproliferative Neoplasms: A Review of What We Know, What We Do Not Know, and Emerging Treatment Strategies.
    McKinnell Z; Karel D; Tuerff D; Sh Abrahim M; Nassereddine S
    J Hematol; 2022 Dec; 11(6):197-209. PubMed ID: 36632576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.